SK Bioscience Signs 200 Billion KRW Contract for Contract Manufacturing of Novavax COVID-19 Vaccine
[Asia Economy Reporter Junho Hwang] SK Bioscience announced on the 24th that it has signed a single sales and supply contract for the contract manufacturing (CMO) of the COVID-19 vaccine 'NYX-CoV2372' with the U.S. pharmaceutical company Novavax, worth 171.7 million USD (2,045,290,400 KRW). The contract period is until the 31st of this month and may change if the contract terms are modified by mutual agreement between the two companies.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Samsung Electronics Labor and Management Reach Dramatic Agreement on Eve of Strike After 6 Months; 10.5% of Semiconductor Performance to Be Distributed
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
